FSD Pharma Inc. (“FSD Pharma” or “the Company”) is a biopharmaceutical company focused on developing innovative therapies for brain and inflammatory disorders to improve patient quality of life. The Company has three drug candidates in its pipeline: (1) LUCID-PSYCH, a unique psychedelic molecule currently undergoing investigational new drug application (IND)-enabling studies with a targeted treatment for neuropsychiatric disorders, including major depressive disorder (MDD); (2) LUCID-MS, a patented, proprietary neuroprotective new chemical entity (NCE), with demonstrated efficacy in preclinical animal models for the potential to reverse and prevent myelin degradation (an underlying cause of Multiple Sclerosis [MS]; (3) FSD-PEA (FSD-201), a patented ultramicronized formulation of palmitolylethonalamide (PEA), with the potential to address a range of inflammatory conditions. PEA interacts with the endocannabinoid system (ECS) in the body and exhibits anti-inflammatory activities. FSD-PEA has completed FDA approved Phase 1 clinical trials with positive topline results and the Company is currently evaluating potential Phase 2 indications.
*The Corporate Snapshot was last updated on March 10, 2022.
